Literature DB >> 2580493

Phototherapy of urticaria pigmentosa: clinical response and changes of cutaneous reactivity, histamine and chemotactic leukotrienes.

B M Czarnetzki, T Rosenbach, G Kolde, P J Frosch.   

Abstract

Ten patients with moderate to very severe urticaria pigmentosa were studied for the therapeutic effect of photochemotherapy (PUVA; six adults) and selective ultraviolet phototherapy (SUP; four adolescents). Despite a high mean PUVA dosage (138.6 +/- 63.4 J/cm2), only two patients had a very good response, while three had a good response and one had a fair response. On the reduction of the frequency of treatments, the symptoms gradually recurred, and several months after the discontinuation of therapy, the clinical status had reached the level prior to PUVA. The results with SUP were even less encouraging. A number of biophysical and biochemical parameters of the skin were studied in five patients before PUVA treatment, immediately after several months of PUVA treatment and again 5 months after the discontinuation of PUVA treatment. Weal and erythema reactions to intracutaneous skin tests remained unchanged after PUVA, while wealing with topically applied dimethylsulfoxide (DMSO) decreased. Transepidermal water loss was markedly reduced over DMSO weals. Histamine levels, which were elevated in lesional but not in normal skin, dropped with PUVA treatment, but after the discontinuation of treatment, they increased again in the lesions. On reverse-phase high-performance liquid chromatography, two main chemotactic factors, leukotriene B4 and 5-HETE, were identified in lesional skin. Chemotactic activity was elevated in both lesional and uninvolved patient skin, reached normal levels at both sites after PUVA and maintained these low levels for several months after the discontinuation of treatment.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2580493     DOI: 10.1007/bf00414106

Source DB:  PubMed          Journal:  Arch Dermatol Res        ISSN: 0340-3696            Impact factor:   3.017


  26 in total

1.  Oral disodium cromoglycate in the treatment of systemic mastocytosis.

Authors:  N A Soter; K F Austen; S I Wasserman
Journal:  N Engl J Med       Date:  1979-08-30       Impact factor: 91.245

2.  Histologic changes in human skin following psoralen therapy.

Authors:  S W BECKER
Journal:  J Invest Dermatol       Date:  1959-02       Impact factor: 8.551

3.  Ultraviolet radiation inhibits alloantigen presentation by epidermal cells: partial reversal by the soluble epidermal cell product, epidermal cell-derived thymocyte-activating factor (ETAF).

Authors:  D N Sauder; F P Noonan; E C DeFabo; S I Katz
Journal:  J Invest Dermatol       Date:  1983-06       Impact factor: 8.551

4.  Selective feed-back inhibition of the 5-lipoxygenation of arachidonic acid in human T-lymphocytes.

Authors:  E J Goetzl
Journal:  Biochem Biophys Res Commun       Date:  1981-07-30       Impact factor: 3.575

5.  Biological and chemical characterization of eosinophil chemotactic factors from human leukocytes.

Authors:  B M Czarnetzki; J Grabbe
Journal:  Agents Actions Suppl       Date:  1983

6.  [Photochemotherapy of psoriasis: clinical experiences with 152 patients (author's transl)].

Authors:  K Wolff; H Hönigsmann; F Gschnait; K Konrad
Journal:  Dtsch Med Wochenschr       Date:  1975-11-28       Impact factor: 0.628

7.  The production and characterisation of products of the lipoxygenase enzyme system released by rat peritoneal macrophages.

Authors:  M V Doig; A W Ford-Hutchinson
Journal:  Prostaglandins       Date:  1980-12

8.  Photochemotherapy (PUVA) in the treatment of urticaria pigmentosa.

Authors:  D Vella Briffa; R A Eady; M P James; S Gatti; S S Bleehen
Journal:  Br J Dermatol       Date:  1983-07       Impact factor: 9.302

9.  Cutaneous biometrics I. The response of human skin to dimethyl sulphoxide.

Authors:  P J Frosch; S Duncan; A M Kligman
Journal:  Br J Dermatol       Date:  1980-09       Impact factor: 9.302

10.  Long-term treatment of systemic mastocytosis with histamine H2 receptor antagonists.

Authors:  G J Johnson; S E Silvis; B Roitman; M Blumenthal; H S Gilbert
Journal:  Am J Gastroenterol       Date:  1980-12       Impact factor: 10.864

View more
  5 in total

1.  Mastocytosis: the great masquerader.

Authors:  James S W Kong; Suzanne Teuber; Rosemary Hallett; M Eric Gershwin
Journal:  Clin Rev Allergy Immunol       Date:  2006-02       Impact factor: 8.667

Review 2.  Leukotrienes in inflammation.

Authors:  M A Bray
Journal:  Agents Actions       Date:  1986-10

Review 3.  Mastocytosis: update on pharmacotherapy and future directions.

Authors:  Juan Carlos Cardet; Cem Akin; Min Jung Lee
Journal:  Expert Opin Pharmacother       Date:  2013-10       Impact factor: 3.889

Review 4.  Mastocytosis.

Authors:  Melody C Carter; Dean D Metcalfe; Hirsh D Komarow
Journal:  Immunol Allergy Clin North Am       Date:  2013-10-07       Impact factor: 3.479

Review 5.  Telangiectasia macularis eruptiva perstans: more than skin deep.

Authors:  Casey E Watkins; Winston B Bokor; Stuart Leicht; George Youngberg; Guha Krishnaswamy
Journal:  Dermatol Reports       Date:  2011-07-29
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.